Novo Nordisk's Counterattack in the Oral Obesity Treatment Market

Novo Nordisk's (NVO) oral semaglutide tablet, Wegovy, recorded Q3 revenue of 5.39 billion Danish kroner (approximately $811 million), significantly exceeding consensus estimates. This contrasts with competitor Eli Lilly (LLY), whose non-peptide small-molecule GLP-1 receptor agonist, foundatio (generic name: orforglipron), is projected to generate Q3 revenue of $184 million, falling $44 million short of estimates. Wegovy secured an 80% share of new prescriptions (NBRx) in the US, successfully defending its market position through strong brand recognition and a robust prescription network. Novo Nordisk plans to expand its launch countries from the current 7 to over 20 by early next year, which is expected to further strengthen its global market leadership.

Madrigal's Rezdiffra Becomes a Blockbuster, Demonstrating Unmet Need in MASH

Madrigal Pharmaceuticals' (MDGL) MASH (metabolic dysfunction-associated steatohepatitis) treatment, Rezdiffra (resmetirom), has joined the ranks of blockbusters, surpassing cumulative revenue of $1.1 billion within 10 quarters of launch. Q3 revenue reached $431 million, exceeding market expectations by $20 million, and the company achieved its first quarterly profit since inception. As a thyroid hormone receptor-beta (THR-β) agonist, Rezdiffra has been recognized for its efficacy in improving liver fibrosis, allowing it to rapidly capture prescription patients despite competition in the obesity treatment market. This demonstrates that the treatment initiation rate is accelerating in the liver disease market, where potential demand was substantial, confirming the commercial viability of the $30 billion MASH market.

Expansion of Axsome's Auvelity Indications and Slower-than-Expected Market Penetration

Axsome Therapeutics' (AXSM) treatment for major depressive disorder (MDD), Auvelity (dextromethorphan/bupropion), received approval for an expanded indication for agitation associated with Alzheimer's disease last April, but Q3 revenue remained at $208 million. While Auvelity, an NMDA receptor antagonist, raised expectations as an alternative mechanism to atypical antipsychotics, it is showing a more gradual start than Wall Street expectations. Although prescriptions for the elderly are gradually expanding, the establishment of diagnostic criteria for new indications and delays in insurance coverage have hindered short-term revenue. Accordingly, Axsome's market capitalization, which once neared $12 billion, has corrected by more than 30% from its peak, highlighting the challenges of establishing a stable market presence.

The Pros and Cons of Early Commercial Prescription Data on Biotech Valuations

These earnings announcements prove that regulatory success in new drug approval does not automatically translate into immediate large-scale revenue. Novo Nordisk and Madrigal are maintaining valuation premiums by achieving strong results based on large-scale production and patient populations with teratogenic risks. Conversely, biotechs entering neuropsychiatric disease markets with few precedents, such as Axsome, must endure the time required for shifts in prescribing practices. Ultimately, the market is strictly differentiating enterprise values based on quarterly prescription volumes and actual patient uptake rates during the commercialization stage, moving beyond simple clinical success.